Berliner Boersenzeitung - Who should get paid for nature's sequenced genes?

EUR -
AED 3.849459
AFN 71.267446
ALL 97.489194
AMD 407.131662
ANG 1.888724
AOA 957.395732
ARS 1052.23996
AUD 1.608928
AWG 1.889106
AZN 1.778344
BAM 1.94835
BBD 2.115818
BDT 125.236374
BGN 1.954483
BHD 0.394975
BIF 3036.718353
BMD 1.048048
BND 1.408315
BOB 7.241313
BRL 6.09607
BSD 1.047898
BTN 88.544945
BWP 14.307296
BYN 3.429786
BYR 20541.735881
BZD 2.112523
CAD 1.463185
CDF 3007.896896
CHF 0.929362
CLF 0.036978
CLP 1020.337634
CNY 7.58493
CNH 7.60312
COP 4601.977666
CRC 532.714856
CUC 1.048048
CUP 27.773265
CVE 110.700038
CZK 25.368204
DJF 186.258433
DKK 7.459213
DOP 63.305535
DZD 140.00766
EGP 52.060203
ERN 15.720716
ETB 129.012117
FJD 2.380379
FKP 0.827242
GBP 0.832233
GEL 2.855918
GGP 0.827242
GHS 16.611978
GIP 0.827242
GMD 74.41137
GNF 9044.651585
GTQ 8.090067
GYD 219.261645
HKD 8.157359
HNL 26.384543
HRK 7.475996
HTG 137.593904
HUF 411.299528
IDR 16692.832925
ILS 3.893576
IMP 0.827242
INR 88.571355
IQD 1373.466575
IRR 44128.050457
ISK 146.100754
JEP 0.827242
JMD 166.433635
JOD 0.743174
JPY 162.013521
KES 135.723264
KGS 90.648567
KHR 4244.593516
KMF 489.959968
KPW 943.242577
KRW 1467.528958
KWD 0.322411
KYD 0.873361
KZT 519.70306
LAK 23009.888592
LBP 93905.078447
LKR 304.924111
LRD 189.120651
LSL 18.979788
LTL 3.094612
LVL 0.633954
LYD 5.119731
MAD 10.475264
MDL 19.084031
MGA 4894.383123
MKD 61.499953
MMK 3404.018207
MNT 3561.266195
MOP 8.401216
MRU 41.822309
MUR 48.632961
MVR 16.203073
MWK 1818.362584
MXN 21.399862
MYR 4.679553
MZN 67.022637
NAD 18.97998
NGN 1768.213504
NIO 38.557204
NOK 11.607569
NPR 141.67231
NZD 1.787898
OMR 0.4035
PAB 1.047993
PEN 3.977374
PGK 4.219178
PHP 61.802851
PKR 291.409517
PLN 4.343765
PYG 8225.236565
QAR 3.81568
RON 4.976446
RSD 116.993815
RUB 106.1678
RWF 1435.825416
SAR 3.934914
SBD 8.756995
SCR 14.316445
SDG 630.380512
SEK 11.596769
SGD 1.410704
SHP 0.827242
SLE 23.659663
SLL 21977.042238
SOS 598.917452
SRD 37.106106
STD 21692.472405
SVC 9.169938
SYP 2633.251262
SZL 18.980071
THB 36.391332
TJS 11.161424
TMT 3.668167
TND 3.317061
TOP 2.454635
TRY 36.149672
TTD 7.1138
TWD 34.1281
TZS 2779.798908
UAH 43.266431
UGX 3872.047297
USD 1.048048
UYU 44.65797
UZS 13498.85466
VES 48.210488
VND 26643.9939
VUV 124.426335
WST 2.925721
XAF 653.458476
XAG 0.033959
XAU 0.000393
XCD 2.832401
XDR 0.799443
XOF 649.260344
XPF 119.331742
YER 261.933367
ZAR 18.957858
ZMK 9433.687606
ZMW 28.899502
ZWL 337.470948
  • RYCEF

    0.1800

    6.79

    +2.65%

  • RBGPF

    -0.5000

    59.69

    -0.84%

  • VOD

    -0.1050

    8.835

    -1.19%

  • CMSC

    0.1050

    24.625

    +0.43%

  • AZN

    0.5980

    63.798

    +0.94%

  • RELX

    0.5250

    45.635

    +1.15%

  • GSK

    0.2350

    33.585

    +0.7%

  • RIO

    0.1250

    62.515

    +0.2%

  • BTI

    -0.1150

    36.965

    -0.31%

  • NGG

    -0.3000

    62.97

    -0.48%

  • BCC

    3.5480

    140.958

    +2.52%

  • JRI

    -0.0030

    13.227

    -0.02%

  • SCS

    0.1550

    13.225

    +1.17%

  • CMSD

    0.1100

    24.37

    +0.45%

  • BCE

    -0.4800

    26.52

    -1.81%

  • BP

    0.3750

    29.455

    +1.27%

Who should get paid for nature's sequenced genes?
Who should get paid for nature's sequenced genes? / Photo: Menahem KAHANA - AFP/File

Who should get paid for nature's sequenced genes?

Much of the vanilla that flavors our ice cream today is artificial, derived from the genetic signature of a plant that hundreds of years ago was known only to an Indigenous Mexican tribe.

Text size:

The plant's sequenced genomic information, available on public databases, was used as the basis for a synthetic flavoring that today competes with vanilla grown in several countries, mainly by small-scale farmers.

Few, if any, benefits of the lucrative scientific advance have trickled down to the communities that gave us vanilla in the first place.

"Wild genetic resources and pharmaceuticals ... are a multi-multi-billion dollar businesses. They clearly are profitable... that's not in dispute," Charles Barber of the World Resources Institute think tank told AFP.

"A great deal of really valuable information has fed into the system from research and utilization of wild genetic resources. And there is no mechanism currently to compensate the people where this information is coming from" in the form of digitally sequenced data, he added.

Much of the information comes from poor countries.

Fair sharing of the gains derived from digitally-stored genetic sequencing data has been a headache for negotiators at the COP16 biodiversity summit into its second week in Cali, Colombia.

At the last conference, in Montreal in 2022, 196 country parties to the UN's Convention on Biological Diversity (CBD) agreed to create a benefit-sharing mechanism for the use of digital sequence information (DSI).

Two years later, they still need to resolve such basic questions as who pays, how much, into which fund, and to whom does the money go?

- 'Cheap and very fast' -

The issue is a complex one.

There is little debate that genetic data-sharing on mostly free-access platforms is crucial for human advancement through medicine and vaccine development, for example.

But how to quantify the value of the sequenced information itself? And should the first people to discover a plant's particular usefulness be compensated?

"Sequencing technology has become so advanced that you can go with a... handheld device a little bit bigger than a cell phone and you can literally sequence a genome in an hour or two and upload it as you sequence it," Pierre du Plessis, a DSI expert and former negotiator for African countries at the CBD told AFP.

These gene sequences are then uploaded to databases which artificial intelligence can mine for potential leads for product development.

DSI is worth an estimated hundreds of billions of dollars a year. And there is a lot of it out there.

"Once the sequence is put into a public database, generally, no benefit-sharing obligations apply," Nithin Ramakrishnan, a researcher with the Third World Network, an advocacy NGO for developing countries, told AFP in Cali.

"Like when the sandalwood sequence information is available in the database whether India wants to share its sandalwood... with a cosmetic company or not, doesn't matter.

- Mandatory -

A point of contention in Cali is a demand from developing countries that payment for DSI use be mandatory, perhaps through a one-percent levy on profits from drugs, cosmetics or other products.

They also want guarantees of non-monetary benefits such as access to vaccines produced from genetic information sequenced from viruses and other pathogens.

"We want real understanding, sector-specific understanding of what non-monetary benefits will be shared and we want the system to be obligatory -- the users should have some form of obligation to share benefits," said Ramakrishnan.

Another sticking point is access for Indigenous people and local communities to DSI funds.

Developing countries want the information on genetic databases to be traceable and "answerable to governments" of the countries where it comes from, said Ramakrishnan.

But rich nations and many researchers oppose such a model which they fear will be too onerous, potentially putting the brakes on scientific pursuits that could benefit all humankind.

With such divergent points of view, observers are doubtful the Cali COP will emerge with any firm decisions on the outstanding questions by closing time on Friday.

The World Wildlife Fund has said "many more rounds of negotiations appear necessary" on DSI.

Added Barber: "I think it's not going to all get solved here."

(K.Müller--BBZ)